3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
8
Melanoma
6
Colonic Neoplasms
4
Rectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Lung Neoplasms
2
Thyroid Neoplasms
1
Solid Tumors
1
Skin Neoplasms
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Neoplasms
1
Lymphatic Metastasis
1
Leukemia, Hairy Cell
1
Hereditary Sensory and Autonomic Neuropathies
1
Gastrointestinal Neoplasms
1
Disease Progression
1
Digestive System Neoplasms
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
57
130-nm albumin-bound paclitaxel
35
Specimen Handling
26
Magnetic Resonance Spectroscopy
21
Albumin-Bound Paclitaxel
21
Fluorouracil
20
Leucovorin
19
Irinotecan
19
Oxaliplatin
17
Biopsy
17
Taxes
16
pembrolizumab
13
Cyclophosphamide
11
Cisplatin
11
fludarabine
10
Cetuximab
9
Capecitabine
8
Nivolumab
7
Carboplatin
7
irinotecan sucrosofate
6
durvalumab
6
dehydroftorafur
6
Radiosurgery
6
Pemetrexed
6
olaparib
5
Ipilimumab
5
Erlotinib Hydrochloride
5
trastuzumab deruxtecan
4
aldesleukin
4
Radiotherapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
encorafenib
×
90 days
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled